AACR-NCI-EORTC - 33rd International Symposium on Molecular Targets and Cancer Therapeutics. Virtual - October 7-10, 2021

IF 0.2 4区医学 Q4 Medicine

Drugs of The Future Pub Date : 2022-01-01 DOI:10.1358/dof.2022.47.1.3393251

E. R. Domenech, P. Cole, X. Bofill

引用次数: 0

Abstract

The 2021 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics meeting, organized by the European Organization for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), was held in a virtual format due to the ongoing COVID-19 pandemic. Historically, 1,500 to 2,500 academics, scientists and pharmaceutical industry representatives come together at this meeting to deliver the latest updates on drug discovery, target selection, cellular and molecular biology, and early clinical trials. This year presentations were delivered both live and on-demand in oral and poster sessions. This report highlights some of the important research presented throughout the meeting.

查看原文本刊更多论文

AACR-NCI-EORTC -第33届分子靶点和癌症治疗国际研讨会。虚拟- 2021年10月7日至10日

由欧洲癌症研究与治疗组织(EORTC)、美国国家癌症研究所(NCI)和美国癌症研究协会(AACR)组织的2021年AACR-NCI-EORTC分子靶点和癌症治疗学会议，由于正在进行的COVID-19大流行，以虚拟形式举行。从历史上看，每年有1500至2500名学者、科学家和制药行业代表齐聚一堂，发表关于药物发现、靶标选择、细胞和分子生物学以及早期临床试验的最新进展。今年的演讲以现场和点播的形式进行，包括口头和海报会议。本报告重点介绍了会议期间提出的一些重要研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drugs of The Future 医学-药学

CiteScore

0.30

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： A leading international, peer-reviewed biomedical research journal publishing articles on topics emerging from the confluence of fields including chemistry, biology, pharmacology, genomics and medicine, and addressed to scientists and researchers involved in drug design, discovery and development, target identification and validation, and the preclinical and clinical development of treatments for common as well as rare and neglected diseases and conditions. The journal publishes monographs containing comprehensive product information on new compounds in development, including synthesis, preclinical pharmacology, pharmacokinetics and metabolism, safety, clinical studies and drug interactions, as well as review articles on a variety of topics, congress and meeting reports.